ENVB Stock Financial Analysis - Enveric Biosciences, Inc. (NasdaqCM) Stock

Overview

Enveric Biosciences, Inc., based in the United States, operates primarily in the biotechnology sector, focusing on advancing cannabinoid science to address unmet medical needs in cancer care. The company dedicates itself to developing novel therapeutic interventions using synthetic cannabinoids, aiming to improve outcomes for cancer patients suffering from side effects associated with current treatments like radiation and chemotherapy. Key projects involve leveraging its proprietary platform to formulate new drug candidates that could potentially ease symptoms such as chemotherapy-induced neuropathy and the psychological burden associated with cancer diagnoses and treatment. Through rigorous clinical development and collaborations, Enveric Biosciences seeks to integrate these innovative solutions into mainstream medical practices, thereby enhancing patient care and treatment experiences.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Enveric Biosciences, Inc. as of June 30, 2025 is -9.96 MM.
The net income for Enveric Biosciences, Inc. as of June 30, 2025 is -9.94 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-9.96	-9.94
2025-03-31		-9.34	-9.30
2024-12-31		-9.63	-9.57
2024-09-30		-8.84	-9.86
2024-06-30		-10.21	-10.59
2024-03-31		-14.07	-15.07
2023-12-31		-16.45	-17.29
2023-09-30		-18.87	-22.53
2023-06-30		-21.07	-22.19
2023-03-31		-20.03	-18.62
2022-12-31		-19.96	-18.47
2022-09-30		-26.81	-51.90
2022-06-30		-24.67	-52.13
2022-03-31		-23.33	-50.25
2021-12-31		-25.29	-48.98
2021-09-30		-17.17	-11.25
2021-06-30		-14.14	-9.11
2021-03-31		-11.55	-9.02
2020-12-31		-5.62	-6.86
2020-09-30		-2.50	-2.92

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31	-10.50	-10.50
2024-12-31	-19.04
2024-09-30	-26.17	-26.17
2024-06-30	-39.63	-39.63
2024-03-31	-85.88	-85.88
2023-12-31	-121.29
2023-09-30	-162.32	-162.32
2023-06-30	-168.11	-168.11
2023-03-31	-163.16	-163.16
2022-12-31	-195.02
2022-09-30	-718.84	-718.84
2022-06-30	-1,041.24	-1,041.24
2022-03-31	-1,249.94	-1,249.94
2021-12-31	-1,555.32
2021-09-30	-498.14	-498.14
2021-06-30	-537.50	-537.50
2021-03-31	-805.51	-805.51
2020-12-31
2020-09-30

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Enveric Biosciences, Inc. as of June 30, 2025 is -6.52 MM.
The cash from financing activities for Enveric Biosciences, Inc. as of June 30, 2025 is 5.88 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-6.52		5.88
2025-03-31	-7.52		5.46
2024-12-31	-7.73		7.67
2024-09-30	-8.17	-0.00	7.02
2024-06-30	-9.98	-0.00	6.40
2024-03-31	-11.56	0.02	5.32
2023-12-31	-14.09	0.01	-1.34
2023-09-30	-15.81	0.01	-1.16
2023-06-30	-17.62	-0.01	6.77
2023-03-31	-17.73	-0.08	8.78
2022-12-31	-17.15	-0.58	18.18
2022-09-30	-17.75	-0.77	18.18
2022-06-30	-15.41	2.31	10.36
2022-03-31	-12.84	2.36	9.42
2021-12-31	-11.46	2.19	24.90
2021-09-30	-9.64	2.34	28.50
2021-06-30	-7.83	-0.72	28.73
2021-03-31	-6.16	-0.72	29.20
2020-12-31	-3.89	-0.04	5.53
2020-09-30	-1.65		1.97

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Enveric Biosciences, Inc. as of June 30, 2025 is -0.32.
The p/book for Enveric Biosciences, Inc. as of June 30, 2025 is 0.76.
The p/tbv for Enveric Biosciences, Inc. as of June 30, 2025 is 0.76.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30	-0.32	0.76	0.76
2025-03-31	-0.29	1.76	1.81
2024-12-31		0.83	0.85
2024-09-30	-0.41	0.80	0.82
2024-06-30	-0.32	0.75	0.77
2024-03-31	-0.32	2.81	3.15
2023-12-31	-0.13	1.24	1.38
2023-09-30	-0.23	1.07	1.13
2023-06-30	-0.35	0.58	0.59
2023-03-31	-0.07	0.15
2022-12-31		0.18	0.27
2022-09-30		0.39	0.62
2022-06-30	-0.22	0.46	0.71
2022-03-31	-1.54	0.31	2.16
2021-12-31	-2.62	0.53	3.68
2021-09-30	-7.10	3.44	3.89
2021-06-30
2021-03-31	-0.54	0.25	0.29
2020-12-31	-0.48	0.97	2.08
2020-09-30

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Enveric Biosciences, Inc. as of June 30, 2025 is 7.00.
The ebit (3y)/ev for Enveric Biosciences, Inc. as of June 30, 2025 is 10.92.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	7.00	10.92
2025-03-31	-17.00	-26.49
2024-12-31	-57.12	-91.12
2024-09-30	-12.94	-38.35
2024-06-30	10.02	20.61
2024-03-31	-5.37	-9.70
2023-12-31	19.23	25.26
2023-09-30	12.54	16.30
2023-06-30	4.05	5.96
2023-03-31	3.50	2.47
2022-12-31	3.68	1.52
2022-09-30	6.98	2.88
2022-06-30	5.55	2.23
2022-03-31	2.75	1.89
2021-12-31	-1.37	-0.83
2021-09-30	-0.21	-0.11
2021-06-30
2021-03-31	0.51	0.26
2020-12-31	-1.57	-0.85
2020-09-30

Management Effectiveness

The roa for Enveric Biosciences, Inc. as of June 30, 2025 is -1.54.
The roe for Enveric Biosciences, Inc. as of June 30, 2025 is -1.72.
The roic for Enveric Biosciences, Inc. as of June 30, 2025 is -2.37.
The croic for Enveric Biosciences, Inc. as of June 30, 2025 is -0.53.
The ocroic for Enveric Biosciences, Inc. as of June 30, 2025 is -1.92.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-1.54	-1.72	-2.37	-0.53	-1.92
2025-03-31	-1.08	-1.48	-6.01	-0.03	-4.85
2024-12-31	-2.29	-5.04	-2.49	-0.29	-2.07
2024-09-30	-1.60	-4.35	-1.96	-0.66	-1.85
2024-06-30	-0.95	-1.32	-2.33	-0.96	-1.78
2024-03-31	-0.88	-1.11	-8.84	-7.89	-7.20
2023-12-31	-0.73	-0.95	-9.22	-6.93	-6.46
2023-09-30	-0.78	-0.98	-4.54	-2.24	-3.61
2023-06-30	-0.65	-0.82	-4.54	-2.24	-3.61
2023-03-31	-1.61	-2.12	-1.63	-0.80	-1.55
2022-12-31	-0.74	-0.94	-2.19	-0.01	-0.75
2022-09-30	-0.75	-0.94	-2.19	-0.01	-0.75
2022-06-30	-2.12	-2.67	-2.29	-0.11	-0.68
2022-03-31	-0.44	-0.59	-2.04	-0.04	-0.52
2021-12-31	-2.75	-3.29	-2.16	0.70	-0.17
2021-09-30	-16.42		-0.20	0.38	-0.41
2021-06-30	-16.42		-0.48	1.06	-0.41
2021-03-31	-23.63		-0.47	1.18	-0.32
2020-12-31	-0.27	-0.65	-1.14	0.25	-0.65
2020-09-30	-26.70

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30